Application of Cda in preparation of product for auxiliary diagnosis or diagnosis of acute kidney injury

By detecting the mRNA level of Cda, the problem of insufficient sensitivity of existing biomarkers is solved, the early and accurate diagnosis of acute renal injury is achieved, the evaluation of the degree of renal injury is improved, and clinical intervention and prevention of chronic kidney disease is promoted. Effect.

CN119020485APending Publication Date: 2024-11-26NANTONG UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411343502.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-25
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

The existing biomarkers are less sensitive to acute renal injury (AKI), making it difficult to achieve early detection and injury grading, resulting in difficulty in clinical intervention, and there are many interference factors as an indicator, affecting the accuracy of diagnosis.

Method used

Cda was used as a biomarker and its mRNA level in human peripheral blood was detected by RT-PCR to evaluate the degree of acute renal injury, and the expression level of Cda was used as the basis for diagnosis.

Benefits of technology

It improves the early diagnosis sensitivity of AKI, can more accurately evaluate the degree of kidney injury, helps to conduct appropriate interventions in clinical practice, and reduces the risk of chronic kidney disease.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119020485A_ABST
    Figure CN119020485A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of disease diagnosis products, and discloses application of Cda in preparation of a product for auxiliary diagnosis or diagnosis of acute kidney injury. The invention provides application of Cda as a biomarker in preparation of a product for auxiliary diagnosis or diagnosis of acute kidney injury, the biomarker is derived from a human peripheral blood sample, the attack degree of acute kidney injury of a to-be-detected individual is evaluated by detecting the expression level of Cda in the human peripheral blood sample, and auxiliary diagnosis or diagnosis of acute kidney injury can be realized. Experiments prove that the increase of the expression quantity of Cda increases the possibility of acute kidney injury of individuals, and vice versa. Therefore, the diagnosis problem of the acute kidney injury existing in the field of medicines can be solved, the disease can be accurately detected and diagnosed as soon as possible, and a timely and effective treatment scheme is provided for patients with the acute kidney injury.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of disease diagnosis products, and more specifically relates to the application of Cda in the preparation of products for auxiliary diagnosis or diagnosis of acute kidney injury. Background Art

[0002] Acute kidney injury (AKI) is an important cause of morbidity and mortality in patients hospitalized for various reasons. It is estimated that the incidence varies from 5% in patients with normal renal function before any surgical operation to 30% in patients admitted to the intensive care unit (ICU). Despite recent advances in diagnosis and treatment, the morbidity and mortality associated with AKI remain highly elevated (40%-60% in patients in the ICU) and have not improved significantly over the past four decades, mainly due to the lack of sensitivity and specificity of tools available for early detection (Clinical Journal of the American Society of Nephrology, 3:1895-1901, 2088). Because of this, the search for early biomarkers has received increasing attention. Moreover, these new biomarkers may be potential tools for early detection, and may also be used to distinguish different degrees of renal injury, thereby determining the detection of patients at risk of developing chronic kidney disease due to severe AKI attacks. Therefore, the development of effective biomarkers will aid in the appropriate intervention for the adequate treatment of AKI in those patients exposed to AKI (such as those admitted to the ICU, those about to undergo cardiac surgery, renal transplant recipients, or those who have already developed AKI), will help to stratify the injury, and detect those patients at risk for the development of chronic kidney disease.

[0003] In clinical practice, the diagnosis of AKI is determined based on the increase in serum creatinine and is performed by assessing the glomerular filtration rate (GFR). Although serum creatinine is used for renal function assessment in patients with chronic kidney disease and in patients with AKI, it is not a good indicator for the following three reasons: 1) A large amount of renal tissue can be damaged without an increase in serum creatinine, and there are obvious examples in kidney transplant donors who have lost 50% of the renal parenchyma and there is no change in serum creatinine levels; 2) Serum creatinine concentration depends on many non-renal factors, such as creatinine conversion to creatinine in skeletal muscle, creatinine release into the blood, etc., so the increase in serum creatinine occurs in a delayed form depending on its release and accumulation; 3) Serum creatinine may also be affected by other factors, such as weight, race, sex, age, drug consumption, muscle metabolism and protein intake. Regarding GFR determination, this may be modified by renal and non-renal damage. For example, a decrease in TGF due to hypovolemia or altered degrees of vasoconstriction or vasodilation in the afferent arterioles, with subsequent increases in serum creatinine, is not associated with tubular or renal injury. All of these factors make early intervention difficult in patients who develop AKI and do not ultimately lead to better outcomes.

[0004] Biomarkers are endogenously produced biomolecules and may be used to detect objective indicators of abnormal biological processes. They can also help detect whether pharmacological interventions can be used to reduce tissue and organ damage caused by pathological processes. Specifically, in patients with AKI, useful biomarkers can help detect the main pathological processes of AKI in an early, accurate and easy manner, i.e., severe proximal tubular damage caused by brush border loss and epithelial polarity. Therefore, the biomarkers can be detected in damaged cells and appear in serum or urine, which can reflect tubular damage associated with AKI. Existing proteins or biomarkers for acute tubular injury, such as Kim-1 and NGAL, have relatively low sensitivity. Even if used in combination, the sensitivity and early detection of AKI can only reach 0.75. Therefore, it is very important to continue to find biomarkers with high sensitivity and can be used for early diagnosis for the prevention and injury classification of clinical AKI. Summary of the invention

[0005] In order to solve the above technical problems, the present invention provides the use of Cda in the preparation of products for auxiliary diagnosis or diagnosis of acute kidney injury.

[0006] Cda (cytidine deaminase) has a Gene ID of 978 in NCBI.

[0007] The first aspect of the present invention provides an application of a biomarker in the preparation of a product for assisting diagnosis or diagnosing acute kidney injury, wherein the biomarker is Cda.

[0008] The Cda protein is an enzyme involved in pyrimidine recovery and an enzyme that catalyzes the deamination of nucleoside analogs. The inventors of the present application have found through a large amount of preliminary research that the cyclic activity of Cda in the pyrimidine salvage pathway is essential for DNA and RNA synthesis. Therefore, Cda deficiency can lead to cell replication stress. In the pathological process of AKI, the renal tubules produce a severe stress response, which affects Cda expression. Therefore, the use of RT-PCR method to detect the mRNA level of Cda as a sensitive biomarker of AKI in human peripheral blood samples can be used to assess the severity of acute kidney injury in the individual to be tested, and to assist in the diagnosis or diagnosis of acute kidney injury.

[0009] In some embodiments of the present invention, the biomarker is derived from a human peripheral blood sample.

[0010] In some embodiments of the present invention, the auxiliary diagnosis or diagnosis is specifically to evaluate the severity of acute kidney injury in the individual to be tested by detecting the expression level of Cda in a human peripheral blood sample.

[0011] In some embodiments of the present invention, compared with the control group of normal people, the Cda gene expression level in the peripheral blood of AKI patients is significantly increased, indicating that the increase in Cda is closely related to the occurrence and development of AKI. It is also found that in AKI patients, the content of AKI marker creatinine is significantly positively correlated with the gene expression of Cda in peripheral blood, that is, as the patient's Cda expression level increases, the degree of AKI response in the body is also enhanced. Therefore, it is proved that the higher the expression level of Cda in the sample, the higher the degree of acute kidney injury in the individual to be tested.

[0012] In some embodiments of the present invention, the expression level is the mRNA expression level of Cda.

[0013] In some embodiments of the present invention, the product is a specific primer for amplifying the Cda gene.

[0014] In some embodiments of the present invention, the product is a probe or chip for detecting the Cda gene.

[0015] The beneficial effects of the present invention are as follows: the present invention proves through experiments that the expression level of Cda is positively correlated with the AKI marker, that is, as the expression level of Cda in patients increases, the degree of AKI response in their bodies also increases. Cda is used as a biomarker to diagnose AKI, has high sensitivity and can be used for early diagnosis, which is very important for clinical practice and can avoid or reduce the occurrence of chronic kidney disease. In addition, the sampling of blood biomarkers is simple and inexpensive. BRIEF DESCRIPTION OF THE DRAWINGS

[0016] Figure 1The test results of the mouse AKI model group and the control group in Example 1 are shown; wherein, Figure A is the plasma urea nitrogen level of the control group and the AKI group, Figure B is the plasma creatinine level of the control group and the AKI group, Figure C' is the renal injury score result of the control group and the AKI group, and Figure C is the HE staining image of the kidney of the control group and the AKI group;

[0017] Figure 2 The single cell data analysis result diagram of the mouse AKI kidney in Example 2 is shown; wherein, Figure A is a single cell clustering diagram of the mouse kidney, Figure B is a marker gene expression diagram defining 17 groups of cells, and Figure C is a diagram of the expression level of the Cda gene in renal tubular cells;

[0018] Figure 3 Figure 1 shows the mRNA expression level of Cda in human peripheral blood; Figure A is the gene expression diagram of peripheral blood Cda, and Figure B is the correlation analysis of Cda gene expression level and creatinine level. DETAILED DESCRIPTION

[0019] The present invention is described below with specific embodiments, but is not intended to be limiting of the present invention.

[0020] The present invention helps to solve the problems of failure to detect AKI early and failure to grade the degree of renal damage suffered by the kidneys in clinical practice, and can accurately detect AKI, thereby appropriately intervening in patients with effective therapies.

[0021] Example 1: Establishment of mouse AKI model.

[0022] Mouse AKI model group: Male BL6J mice were used and anesthetized with Avertin (10 mg / kg, ip). Laparotomy was performed, and the renal pedicle was cut and the renal artery was ligated to interrupt the blood flow to the kidney.

[0023] Control group: male BL6J mice.

[0024] 24 hours after surgery, peripheral blood and kidneys of male BL6J mice in the mouse AKI model group were collected from the mouse AKI model group (AKI) and the control group (Ctrl). Plasma was used to detect plasma urea nitrogen and creatinine, and kidneys were stained with HE to assess the grade of renal injury. The results are shown in the figure. Figure 1 As shown. Figure 1 It can be seen that the plasma urea nitrogen and creatinine levels in the AKI group were significantly increased, and the renal tubular damage was obvious. HE staining showed renal tubular dilatation, interstitial edema, thinning of the tubular wall, and the presence of foreign bodies in the tubular lumen. The injury grade was 3.

[0025] Example 2: Single-cell data analysis of mouse AKI kidney

[0026] Single-cell sequencing was performed on the kidneys of the mouse AKI model group (AKI) and control group (Ctrl) collected in Example 1, and single-cell data were analyzed using R studio. Specifically, the cells were first grouped, such as Figure 2 As shown in Figure A, there are 17 different cell populations in the mouse kidney, and the yellow box is the renal tubular cell population. Figure 2 As shown in Figure B, Slc27a2 and Lrp2 are marker genes for renal tubules. Figure 2 As shown in Figure C, it can be seen that the Cda gene is highly expressed specifically in renal tubular cells.

[0027] Example 3: Detection of Cda expression level in human peripheral blood

[0028] Peripheral blood samples of 9 AKI patients were collected from the Affiliated Hospital of Nantong University (AKI). According to the international standard of AKIN, AKI was determined by comparing the serum creatinine level with that of the healthy control group to be greater than 0.3 mg / dl. At the same time, peripheral blood samples of 9 people in the same age group who underwent physical examination were collected as the control group (Ctrl). The expression level of Cda in peripheral blood was detected by RT-PCR.

[0029] Peripheral blood leukocyte extraction: Take 3-5ml of venous blood, anticoagulate with EDTA, and centrifuge at 2500rpm for 10min; carefully aspirate the upper plasma and divide it into 3 0.5ml centrifuge tubes; add 3 times the volume of hemolysate to the blood cells, shake well, and place in an ice bath for 15min; centrifuge at 2500rpm for 10min, and discard the supernatant; add 10ml of hemolysate, shake well, and place in an ice bath for 15min; centrifuge at 3000rpm for 10min, and discard the supernatant; invert the centrifuge tube and remove the residual liquid; obtain the leukocytes and freeze them at -80℃ to avoid repeated freezing and thawing; the interval between blood collection and leukocyte separation should not exceed 2h at room temperature and not exceed 5h at 4℃ to prevent leukocyte autolysis.

[0030] RNA extraction: After the frozen leukocytes are thawed, add 1ml sterile PBS to resuspend, centrifuge at 4℃1000rpm for 1min; discard the supernatant and add 1ml TRIzol to lyse the cells, mix by blowing with the pipette tip; let it stand at room temperature for 5min, transfer the supernatant to a 1.5ml EP tube; centrifuge at 12000rpm for 5min, take the supernatant, add chloroform, shake and mix, and let it stand at room temperature for 15min to allow it to separate naturally; centrifuge at 4℃12000rpm for 15min, the sample is separated into three layers, a yellow organic layer, and a colorless aqueous phase in the middle and upper layers, with RNA mainly in the aqueous phase; carefully pipette the upper aqueous phase into a new 1.5ml EP tube, add an equal volume of ice-cold isopropanol, and let it stand at -20℃ for 1h; centrifuge at 4℃12000rpm for 10min; discard the supernatant, add 1ml 75% ethanol, gently shake the EP tube to suspend the precipitate; centrifuge at 4℃8000rpm for 5min, discard the supernatant, and dry at room temperature for 5-10min; use 50μl Dissolve RNA precipitate in DEPC water, detect RNA concentration, and store at -80℃ for future use;

[0031] cDNA synthesis reaction: 4.0μl 5× Prime Script Buffer, 1.0μg Total RNA, 20ul RNaseFree ddH2O, gently mix, react at 37℃ for 15min, react at 85℃ for 5s, and gradually cool to 4℃;

[0032] RT-qPCR reaction: 10.0μl SYBR Green Premix Ex Taq II, 1.0μl Forward Primer, 1.0μl Reverse Primer, 2.0μl cDNA, 20ul RNase Free ddH2O, fully mix the reaction solution, pre-denature at 95℃ for 30s; denature at 95℃ for 5s, anneal at 60℃ for 30-34s, 40 cycles;

[0033] (6) The Ct value of the internal reference gene GAPDH was normalized to the Ct value of the target gene, and the expression difference of the sample gene was relatively quantitatively analyzed using the 2-△△Ct method to obtain the expression level of cda.

[0034] Figure 3 The comparison chart of Cda mRNA expression level in human peripheral blood is shown in Figure 2. Figure 3 A It can be found that the expression level of Cda in the peripheral blood of AKI patients was significantly higher than that of the control group (p < 0.0001), suggesting that the increase in Cda levels is closely related to the occurrence and development of AKI. Figure 3Data B shows that in AKI patients, the content of creatinine, a damage marker, is significantly positively correlated with the level of Cda in peripheral blood, that is, as the expression level of Cda in patients increases, the degree of AKI in the body increases. Therefore, it is proved that the expression level of Cda can be used as a detection marker of AKI, and the degree of renal injury can be evaluated by the level of its gene expression.

[0035] The above are only preferred specific implementation modes of the present invention, but the protection scope of the present invention is not limited thereto. Any technician familiar with the technical field can make equivalent replacements or changes according to the technical solutions and inventive concepts of the present invention within the technical scope disclosed by the present invention, which should be covered by the protection scope of the present invention.

Claims

1. Use of a biomarker in the preparation of a product for assisting diagnosis or diagnosing acute kidney injury, characterized in that: The biomarker is Cda.

2. The use according to claim 1, characterized in that: The biomarkers are derived from human peripheral blood samples.

3. The use according to claim 1, wherein the auxiliary diagnosis or diagnosis is specifically to assess the severity of acute kidney injury in the individual to be tested by detecting the expression level of Cda in human peripheral blood samples.

4. The use according to claim 3, characterized in that: The higher the expression level of Cda in the sample from the individual to be tested, the higher the severity of acute kidney injury in the individual to be tested.

5. The use according to claim 3 or 4, characterized in that: The expression level is the mRNA expression level of Cda.

6. The use according to any one of claims 1 to 4, characterized in that: The product is a specific primer for amplifying the Cda gene.

7. The use according to any one of claims 1 to 4, characterized in that: The product is a probe or chip for detecting the Cda gene.